Singapore markets closed

TFF Pharmaceuticals, Inc. (TFFP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0300-0.5100 (-20.08%)
At close: 04:00PM EDT
2.2600 +0.23 (+11.33%)
Pre-market: 08:27AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5400
Open2.6700
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.0100 - 2.6700
52-week range2.0100 - 19.7500
Volume85,519
Avg. volume35,325
Market cap5.114M
Beta (5Y monthly)1.29
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering

    FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants t

  • GlobeNewswire

    TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

    FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,66

  • GlobeNewswire

    TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting

    Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”)